Extension to scope to be applied for
People normally inhale about 200 conidia of aspergillus fumigatus species complex every day. For the normal healthy individual the immune response is efficient and prevents any disease from occurring. In the immunocompromised, this can lead to fungal invasion into the lungs and other organs. Detection of the antigen galactomannan (GM), in serum and bronchoalveolar lavage (BAL) is recommended as a criterion in the early diagnosis of Invasive Aspergillosis, following EORTC/MSG guidelines (2008).
PURPOSE OF PROGRAMME:
To provide EQA for laboratories determining the presence of galactomannan antigen in serum, BAL and cerebrospinal samples
PROGRAMME OF ANALYSIS:
Results are entered online via the UK NEQAS secure website. The distribution is open for two weeks. Intended results are usually uploaded the day after closing date. Late results are not accepted after intended results are uploaded.
Qualitative detection in accordance with the intended result. General descriptive statistics.
PERSISTENT POOR PERFORMANCE:
See the Annual Directory for UK and Irish participants only
The first distribution of UK NEQAS for Microbiology was sent out by the then Public Health Laboratory Services on the 1st of May 1971 organised by Dr Peter Crone. This distribution consisted of one scheme, three bacteriology specimens, sent to 67 laboratories in the UK. One of our recent distributions consisted of 12 different schemes, comprising 8 bacteriology, 13 serology, 10 molecular and 9 mycology specimens, and sent to 53 countries representing over 1300 laboratories. UK NEQAS for Microbiology, operated by Public Health England, is a UKAS accredited proficiency testing provider No. 4715.